Background and Aim: Intraductal papillary mucinous tumor (IPMT) of the pancreas can be divided into three clinically distinct subtypes: main duct type, branch duct type and mixed type. Although it ...

Scientists have developed a new mRNA vaccine to treat pancreatic cancer that may extend patients' lifespans by 8 to 10 years.

Some IPMNs primarily involve the main pancreatic duct, while others involve the branch ... also at risk for other malignancies and should undergo colonoscopy and close cancer surveillance. Serous ...

including pancreatic cancer. Desai discovered that in the ductal organoids, oncogenic GNAS induced PKA-dependent IPMN-associated phenotypes. Surprisingly, the oncogene also increased cell ...

Researchers have developed a simple blood test to detect pancreatic cancer before it spreads to other sites in the body. The ...

A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study published in the journal Nature.

A new blood test could help doctors detect pancreatic cancer earlier, potentially improving survival rates for one of the ...

These differences were also seen in people who didn’t have pancreatic cancer, but were at high risk of the disease because they have a condition known as intraductal papillary mucinous neoplasms.

According to the preoperative localization of the IPMT, different types of pancreatic resection were performed. Of 67 cases of IPMT, 17 cases (25.4%) were excised by Whipple's operation ...